Compare Aurobindo Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 18.0 36.2 49.6% View Chart
P/BV x 3.9 4.2 92.5% View Chart
Dividend Yield % 0.3 0.5 55.6%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
CIPLA
Mar-20
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs830586 141.8%   
Low Rs527357 147.7%   
Sales per share (Unadj.) Rs333.9207.0 161.3%  
Earnings per share (Unadj.) Rs40.418.6 217.0%  
Cash flow per share (Unadj.) Rs51.833.2 156.1%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.40.8 43.4%  
Book value per share (Unadj.) Rs237.1195.5 121.3%  
Shares outstanding (eoy) m585.91806.35 72.7%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.02.3 89.3%   
Avg P/E ratio x16.825.3 66.4%  
P/CF ratio (eoy) x13.114.2 92.3%  
Price / Book Value ratio x2.92.4 118.8%  
Dividend payout %6.221.5 28.8%   
Avg Mkt Cap Rs m397,569379,912 104.6%   
No. of employees `00017.925.8 69.1%   
Total wages/salary Rs m25,84930,270 85.4%   
Avg. sales/employee Rs Th10,956.96,459.6 169.6%   
Avg. wages/employee Rs Th1,447.71,171.2 123.6%   
Avg. net profit/employee Rs Th1,324.3580.2 228.2%   
INCOME DATA
Net Sales Rs m195,636166,949 117.2%  
Other income Rs m1,5533,442 45.1%   
Total revenues Rs m197,189170,391 115.7%   
Gross profit Rs m39,51932,060 123.3%  
Depreciation Rs m6,68011,747 56.9%   
Interest Rs m2,6261,974 133.1%   
Profit before tax Rs m31,76721,782 145.8%   
Minority Interest Rs m27-475 -5.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2696,312 115.2%   
Profit after tax Rs m23,64514,995 157.7%  
Gross profit margin %20.219.2 105.2%  
Effective tax rate %22.929.0 79.0%   
Net profit margin %12.19.0 134.6%  
BALANCE SHEET DATA
Current assets Rs m153,645117,038 131.3%   
Current liabilities Rs m120,42943,931 274.1%   
Net working cap to sales %17.043.8 38.8%  
Current ratio x1.32.7 47.9%  
Inventory Days Days13596 141.2%  
Debtors Days Days6485 74.9%  
Net fixed assets Rs m103,909107,424 96.7%   
Share capital Rs m5861,613 36.3%   
"Free" reserves Rs m138,322156,018 88.7%   
Net worth Rs m138,908157,630 88.1%   
Long term debt Rs m1,80023,693 7.6%   
Total assets Rs m264,544236,626 111.8%  
Interest coverage x13.112.0 108.8%   
Debt to equity ratio x00.2 8.6%  
Sales to assets ratio x0.70.7 104.8%   
Return on assets %9.97.2 138.5%  
Return on equity %17.09.5 178.9%  
Return on capital %23.812.8 185.6%  
Exports to sales %49.633.0 150.2%   
Imports to sales %18.80-   
Exports (fob) Rs m97,09155,175 176.0%   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31656,036 173.7%   
Fx outflow Rs m40,5896,764 600.1%   
Net fx Rs m56,72749,272 115.1%   
CASH FLOW
From Operations Rs m16,22030,685 52.9%  
From Investments Rs m-28,7681,040 -2,765.1%  
From Financial Activity Rs m19,191-29,488 -65.1%  
Net Cashflow Rs m6,6562,340 284.4%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  GSK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Rallied 834 Points Today(Closing)

After staging a gap-up opening, Indian share markets extended gains as the session progressed and rallied nearly 2%, boosted by realty and finance stocks.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 19, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS